Phase 1/2 trial of LB-001
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs LB 001 (Primary)
- Indications Methylmalonic acidaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors LogicBio Therapeutics
- 13 Aug 2019 According to an LogicBio Therapeutics media release, this trial is expected to begin in 1H 2020 and preliminary data is anticipated in 2H 2020.
- 13 Aug 2019 According to an LogicBio Therapeutics media release, the company plans to file an Investigational New Drug application for LB-001 in the fourth quarter of 2019 and the details regarding clinical trial size, endpoints and timelines to be communicated upon IND acceptance.
- 22 Feb 2019 According to a LogicBio media release, Dr. Kenneth Huttner will lead IND-enabling studies and upcoming clinical trials of LB-001.